Bio-Matrix Scientific Group, Inc - BMSN

Bio-Matrix Scientific Group, Inc., through its subsidiary, Regen BioPharma, Inc., intends to engage primarily in the development of regenerative medical applications. The company develops HemaXellerate I, a patient-specific composition of cells that have been demonstrated to repair damaged bone marrow and stimulate production of blood cells based on previous animal studies; and HemaXellerate II, an early stage development product for stimulating bone marrow hematopoetic stem cell repair and proliferation. It also develops dCellVax, an early stage development product that is intended to treat dendritic cells of the cancer patient using plasmid DNA; NR2F6, a research project to treat myelodysplastic syndrome; and Tcellvax, an autologous cellular product. Bio-Matrix Scientific Group, Inc. was founded in 2005 and is based in La Mesa, California.